ReShape Lifesciences Inc.·4

Aug 13, 4:29 PM ET

STANKOVICH THOMAS 4

4 · ReShape Lifesciences Inc. · Filed Aug 13, 2024

Insider Transaction Report

Form 4
Period: 2023-11-30
STANKOVICH THOMAS
Chief Financial Officer
Transactions
  • Sale

    Common Stock, $0.001 par value per share

    2023-11-30$0.23/sh39$922,910 total
  • Sale

    Common Stock, $0.001 par value per share

    2024-02-29$0.17/sh43$722,825 total
  • Sale

    Common Stock, $0.001 par value per share

    2023-12-31$0.25/sh42$1122,868 total
  • Sale

    Common Stock, $0.001 par value per share

    2024-05-31$0.25/sh48$1222,777 total
Footnotes (1)
  • [F1]On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

Documents

1 file
  • 4
    primary_doc.xmlPrimary

    PRIMARY DOCUMENT